clindamycin-2-phosphate (Clindets)

05/01/1981 - "One percent clindamycin phosphate in equal parts of alcohol and water is apparently beneficial for some, but not for all patients with inflammatory acne."
03/01/2013 - "Clindamycin phosphate 1.2%-BPO 2.5% gel is an effective, safe, and well-tolerated treatment in adolescents with moderate to severe acne. "
07/01/2012 - "Clindamycin phosphate 1.2%/BPO 2.5% gel has been shown to be effective, safe, and well tolerated in moderate to severe acne in adolescents with skin of color."
01/01/2005 - "The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris."
09/01/1986 - "The efficacy and skin tolerance of 1 percent clindamycin phosphate lotion were compared with those of the placebo for the lotion in a randomized, double-blind, 12-week study in forty-six patients with moderate to severe acne vulgaris. "

08/01/1982 - "[Clinical evaluation of clindamycin-2-phosphate in the treatment of various otorhinolaryngological infections--a multi-center study using an identical protocol]."
07/01/1981 - "The other patients received one infection of 300 mg of clindamycin phosphate 30 min to 1 h before surgery. "
09/01/1977 - "The treatment of abdominal and gynaecological infections with parenteral clindamycin phosphate."
05/01/1977 - "[Clinical application of clindamycin-2-phosphate to otorhinolaryngological infections (author's transl)]."
02/01/1977 - "[Clinical experience with clindamycin-2-phosphate in dermatological infections (author's transl)]."

07/01/2010 - "To develop more effective treatment for bacterial vaginosis, bioadhesive film formulations of clindamycin phosphate (CL) for vaginal delivery were studied. "
07/01/1990 - "Blinded intravaginal clindamycin phosphate treatment cured bacterial vaginosis in 93.5% (43 of 46) of patients 4-7 days after therapy, compared with 25.0% (four of 16) of patients receiving placebo (P less than .001). "
06/01/1995 - "In recent clinical studies, clindamycin phosphate cream administered intravaginally has been shown to be efficacious in the treatment of bacterial vaginosis (BV). "
01/01/2000 - "To asses the efficiency of the 2% clindamycin phosphate creme given in 3 and 7 daily courses officially designer for the treatment of bacterial vaginosis (BV). "
07/01/1990 - "Bacterial vaginosis: treatment with topical intravaginal clindamycin phosphate."

12/01/2012 - "Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial."
12/01/2012 - "Thirty rosacea subjects were enrolled to assess their response to the use of clindamycin phosphate 1.2% and tretinoin 0.025% gel (ZIANA; Medicis Pharmaceutical Corporation, Scottsdale, AZ) for a period of 12 weeks. "
03/01/2012 - "A combination gel of clindamycin phosphate 1.2% and tretinoin 0.025% may improve the telangiectatic component of rosacea and appears to better treat the erythemotelangiectatic subtype of rosacea rather than papulopustular subtype. "
03/01/2012 - "To assess the preliminary efficacy and safety of a combination gel consisting of clindamycin phosphate 1.2% and tretinoin 0.025% on papulopustular rosacea after 12 weeks of usage. "
03/01/2012 - "A combination topical clindamycin phosphate 1.2% and tretinoin 0.025% gel is efficacious for acne vulgaris, and may be helpful for rosacea, since acne vulgaris and rosacea shares many similar clinical and histologic features. "

06/01/2012 - "Thus, we can expect that intraperitoneal administration of <600 mg clindamycin phosphate per every 6 hr dialysate could be maintained over 5 μg/mL in patients with peritonitis. "
06/01/2012 - "The clindamycin concentration in the dialysate was greater than the effective concentration (5 μg/mL) at 6.87 μg/mL up to 6 hr. So, 600 mg clindamycin phosphate per every 6 hr dialysate is effective for treatment of peritonitis. "
12/01/1986 - "These results support the practice of not only administering intraperitoneal clindamycin phosphate to treat CAPD-related peritonitis, but using this route of administration to treat systemic infections due to susceptible bacteria in patients without intravenous access."
06/01/2012 - "Twelve patients (six men and six women; all older than 25 years), mean CAPD duration of 38.2 months with various origins without peritonitis, received 600 mg clindamycin phosphate mixed with only the first 2-L dialysate (1.5% dextrose). "
06/01/2012 - "We evaluated the pharmacokinetics of clindamycin and the dose of clindamycin phosphate necessary to treat peritonitis after intraperitoneal administration of clindamycin phosphate to patients on continuous ambulatory peritoneal dialysis (CAPD). "